Lipoprotein(a) [Lp(a)] is a unique lipoprotein that has emerged as an independent risk factor for cardiovascular vascular disease. Data from case control, epigenetic and mendelian randomization studies indicate that people with elevated Lp(a) have a two-fold to four-fold increased risk of cardiovascular events compared to people with low Lp(a) levels. Despite this risk, awareness of Lp(a) is still very low among health care providers. Even cardiologists often overlook Lp(a), in part because Lp(a) is not as well-understood as other risk factors and treatment options are still very limited.

This book offers an authoritative and comprehensive overview of Lipoprotein(a). It provides an in-depth review of all aspects of Lp(a), from pathophysiology to metabolism. Chapters offer the reader a contemporary view of the important roles of Lp(a) as a risk factor for cardiovascular disease. In addition, this volume discusses the clinical implications of elevated Lp(a) and current and future therapies. Lipoprotein(a) is an essential resource for physicians, medical students, residents, fellows, and allied health professionals in lipidology, cardiology, endocrinology, pharmacotherapy, and health promotion and disease prevention.

Provides comprehensive coverage of lipoprotein(a) and its role in the development of cardiovascular disease Highlights current and future therapies for combating high levels of lipoprotein(a) Brings awareness to an often overlooked risk factor of heart attacks and other serious cardiovascular events

Autorentext
Karam Kostner, MD, Ph.D., FRACP,  FCSANZ Associate Professor of Medicine

University of Queensland and Mater Hospital Brisbane, Australia

Gerhard M. Kostner, Ph.D. Emeritus Professor of Biochemistry and Molecular Biology

Medical University of Graz, Austria Graz, Austria

Peter P. Toth, M.D. , PhD, FAHA, FESC, FACC

Adjunct Professor of Medicine

Division of Cardiology

Johns Hopkins University School of Medicine

Baltimore, Maryland  USA

Inhalt
60 years of Lp(a) research-From Ouchterlonys double diffusion to a significant risk factor for CHD.- Lp(a) structure and composition.- Genetics of Lipoprotein(a).- Lp(a) metabolism.- Contemporary aspects of Lp(a) metabolism and therapies based on tracer kinetic methods.- Role of Proprotein Convertase Subtilisin Kexin type 9 in Lipoprotein(a) Metabolism.- The Role of Cell Surface Receptors in Lp(a) Metabolism.- Physiological Roles And Functions Of Lipoprotein(a).- The role of Lp(a) in Atherosclerosis: An overview.- Role of macrophages in Lp(a) pathophysiology.- Thrombosis, Inflammation and Lipoprotein(a): Clinical Implications .- The role of the kidney in Lp(a) physiology and pathophysiology.- Lp(a) as a cardiovascular risk factor.- Lp(a) and aortic valve stenosis, stroke, and other non-coronary cardiovascular diseases.- Lp(a) in cardiovascular disease: Evidence from Large Epidemiological Studies.- Lipoprotein(A) And Immunity.- When to measure Lp(a) .- Measurement of Lipoprotein (a) in the Clinical Laboratory.- Standardization of analytical methods for the measurement of Lipoprotein(a): bridging past and future initiatives.- Establishing an SI-traceable Reference Measurement System for Lp(a), based on Quantitative Protein Mass Spectrometry and Molar Units.- Compounds that impact Lp(a) concentrations.- Antisense oligonucleotide therapy to treat elevated lipoprotein(a).- Lipoprotein apheresis for reduction of Lipoprotein(a).- Elevated Lp(a) - Why Should I Test For It, If I Cannot Treat It? A Patient's Perspective .- Burning unanswered questions Therapy.